Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Chemotherapy-Related Cognitive Impairment

ClinicalTrials.gov lists 39 trials for Chemotherapy-Related Cognitive Impairment or a narrower condition beneath it.

MeSH D000084202 Chemically-Induced Disorders C25 F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 5 Phase 3 Phase 3 2 Phase 4 Phase 4 1 Not applicable Not applicable 20 Observational Observational 9 Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 5 Phase 3 Phase 3 2 Phase 4 Phase 4 1 Not applicable Not applicable 20 Observational Observational 9

Trials per phase (log scale)

39 of the 39 trials are tagged with Chemotherapy-Related Cognitive Impairment itself; the rest are tagged with a narrower condition beneath it.

Get the Chemotherapy-Related Cognitive Impairment report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Chemotherapy-Related Cognitive Impairment trials start? (17)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 6

2001: 1 trials (Observational 1) 2002: 1 trials (Phase 2 1) 2006: 1 trials (Phase 1 1) 2010: 1 trials (Phase 2 1) 2011: 1 trials (Observational 1) 2013: 1 trials (Observational 1) 2015: 3 trials (Not applicable 2, Phase 2 1) 2016: 2 trials (Observational 1, Not applicable 1) 2018: 1 trials (Not applicable 1) 2019: 1 trials (Not applicable 1) 2020: 1 trials (Not applicable 1) 2021: 4 trials (Observational 2, Not applicable 2) 2022: 5 trials (Observational 1, Not applicable 3, Phase 3 1) 2023: 3 trials (Not applicable 1, Phase 2 2) 2024: 5 trials (Not applicable 4, Phase 4 1) 2025: 6 trials (Observational 2, Not applicable 3, Phase 3 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2
2025 6
2024 5
2023 3
2022 5
2021 4
2020 1
2019 1
2018 1
2016 2

No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 14 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Chemotherapy-Related Cognitive Impairment trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1
Phase 1/2 1
Phase 2 5
Phase 3 2
Phase 4 1
Not applicable 20
Observational 9

How many Chemotherapy-Related Cognitive Impairment trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 4
Recruiting 7
Enrolling by invitation 2
Active, not recruiting 1
Completed 13

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Chemotherapy-Related Cognitive Impairment trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Bright Cloud International Corp 1
Celgene Corporation 1
Instituto Jalisciense de Cancerologia 1

Which drugs are being tested for Chemotherapy-Related Cognitive Impairment? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Butylphthalide 1

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
AG chemotherapy 1
Doxorubicine 1
N Acetyl Cysteine 1
Ganglioside-Monosialic Acid 1
Study of the adverse effects of long-term oncological treatments 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Chemotherapy-Related Cognitive Impairment trials report? (5)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Blood bilirubin increased 1 1
Lung Infection 1 1
MRSA positive infection in toe 1 1
Non-cardiac chest pain 1 1
White blood cell decreased 1 1

Which publications cover Chemotherapy-Related Cognitive Impairment? (13)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages